{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-026866","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2022-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.249315+00:00","generated_at":"2026-06-21T01:00:01.206665+00:00","sec_items":["1.01","5.03","3.02","3.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Revelation Biosciences issues CEO one share of Series A Preferred with 50M votes to secure reverse stock split approval","bullets":["CEO James Rolke purchased one share of Series A Preferred for $5,000 cash.","Preferred carries 50,000,000 votes, only on proposals to increase authorized common stock and effect reverse stock split.","Preferred votes in proportion to common stock votes on those proposals; no other voting rights.","Non-convertible, no dividends, no liquidation rights; redeemable at $5,000 upon board order or automatically upon reverse split effectiveness.","Transfer restricted without board consent; issuance exempt under Section 4(a)(2)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-026866","json":"https://secwatch.observer/filing/0000950170-22-026866.json","markdown":"https://secwatch.observer/filing/0000950170-22-026866.md","text":"https://secwatch.observer/filing/0000950170-22-026866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017022026866/0000950170-22-026866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017022026866/revb-20221219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T01:00:01.206665+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f32e587ea5acbe8fb6e30d21ba3d658fd9c8a084","claim":"REVELATION BIOSCIENCES, INC.: Filed certificate of designation creating a new series of Preferred Stock with designated voting rights, redemption provisions, and other preferences, effective upon filing (effective 2022-12-19).","evidence_excerpt":"On December 19, 2022, the Company filed a certificate of designation (the “Certificate of Designation”) with the Secretary of State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the share of Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017022026866/0000950170-22-026866-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2022-12-19"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}